Psychosis Clinical Trial
Official title:
Effectiveness of Mindfulness Intervention in Prevention of Relapse in Psychosis
Practicing mindfulness is popular and well-accepted for its benefits in improving mental and
physical health. In particular, its benefits in promoting resilience to stress and well-being
have been shown in studies involving different psychiatric conditions, as well as preventing
relapse in patients with depressive disorders. However, its role in relapse prevention among
patients with psychosis has not been tested.
The investigators therefore propose a multi-site, single-blind, 12-month randomized
controlled trial in Hong Kong to examine the effectiveness of mindfulness intervention in
prevention of relapse among 152 remitted psychosis patients.
Objectives and hypotheses
1. Primary objective:
• To examine if mindfulness-based intervention can reduce rates of relapse at 1 year in
remitted patients with psychosis.
2. Secondary objectives:
- To test whether mindfulness-based intervention can reduce stress, depressive
symptoms, and improve functioning and quality of life at 1 year in remitted
patients with psychosis.
Participants Patients will be recruited from the Early Assessment Service for Young people
with psychosis (EASY). This service provides specialized psychiatric care for the first three
years for young persons with first episode psychosis and covers the entire population of Hong
Kong of approximately seven million people. The sample will consist of 152 fully remitted
patients diagnosed with schizophrenia or non-affective psychosis (schizophreniform disorder,
schizoaffective disorder, brief psychotic disorder, or psychotic disorder not otherwise
specified)
Study design This is a single-blind, 12-month, multi-site, randomized controlled trial (RCT)
of the effect of mindfulness intervention in preventing relapse in remitted psychosis.
Patients will be randomized into either having 7-week mindfulness-based intervention or
7-week psychoeducation groups. The study consists of the following time points: baseline
(before the start of intervention), at 7-week after the intervention, and then monthly for
the remaining 12 months following end of the intervention. Relapse will be assessed monthly
during the 1-year follow-up period. Patients will be terminated from the study if relapse
occurs during the follow up. The study will be carried out in accordance with Good Clinical
Practice and with the Declaration of Helsinki. The study have sought for approval from the
Institutional Review Boards at each site. All participants will be required to provide
written informed consent. Patients will be individually randomized to one of the two parallel
groups: 7-week mindfulness intervention or 7-week psychoeducation.
Procedures
Mindfulness intervention group All patients in the mindfulness group will receive EASY
service and 7 weekly-session mindfulness-based intervention for psychosis (MBI-p). It is a
protocol-based, low intensity mindfulness developed to help patients to achieve greater sense
of peace and calmness, and facilitate participants in handling everyday stress and conflicts.
MBI-p consists of seven 1.5-hour group sessions, and each group will have 2-6 participants.
Each MBI-p session has the following components: engagement and introduction, mindfulness
practices, daily life application and consolidation of learning. Facilitators in conducting
the MBI-p will be trained by experienced investigators.
Psychoeducation group All patients in the psychoeducation group will receive EASY service and
7 weekly-session psychoeducation. Each psychoeducation will last for 1.5 hours, including
topics on the signs and symptoms of psychosis, aetiology of psychosis and medication usage.
Assessments The primary outcome of relapse will be assessed using the Positive and Negative
Syndrome Scale (PANSS) and the Clinical Global Impressions (CGI) Scale (Guy, 1976). Relapse
will be assessed before (baseline) and after intervention, and then monthly for 12 months.
When patients experience a psychotic relapse at any point during this 12-month period, their
participation will be terminated.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04929938 -
Application of UP for Transdiagnostic Treatment of Emotional Disorders for UHR for Psychosis Patients
|
N/A | |
Recruiting |
NCT05863572 -
Strengthening Care in Collaboration With People With Lived Experience of Psychosis in Uganda
|
N/A | |
Completed |
NCT04277585 -
Improving Access to Early Psychosis Coordinated Specialty Care
|
N/A | |
Recruiting |
NCT06197048 -
Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Terminated |
NCT04404712 -
FAAH Availability in Psychiatric Disorders: A PET Study
|
Early Phase 1 | |
Recruiting |
NCT05769933 -
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
|
||
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Not yet recruiting |
NCT05558332 -
Youth Nominated Support Team
|
N/A | |
Not yet recruiting |
NCT05358457 -
Pilot Study to Evaluate the Effectiveness of Online Familiar Metacognitive Training (MCTf)
|
N/A | |
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Completed |
NCT02895269 -
COllaborative Shared Care to IMprove Psychosis Outcome
|
N/A | |
Recruiting |
NCT02622048 -
Understanding and Helping Families: Parents With Psychosis
|
N/A | |
Completed |
NCT02653729 -
Cbt for Psychosis and Affect on Psychosis Symptoms
|
Phase 2 | |
Completed |
NCT02531243 -
Computer-Aided Learning for Managing Stress
|
N/A | |
Completed |
NCT02733575 -
Compassion Focused Therapy for Distressing Experiences
|
N/A | |
Not yet recruiting |
NCT02244970 -
Mindfulness RCT for Early Psychosis
|
N/A | |
Enrolling by invitation |
NCT01364818 -
Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment
|
N/A | |
Withdrawn |
NCT00786318 -
Ziprasidone vs Standard Therapy for Agitated Patients in the ED
|
Phase 4 | |
Recruiting |
NCT00722163 -
A Randomized Controlled Trial of Individual Therapy for First Episode Psychosis
|
Phase 0 |